| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
|
Br J Pharmacol
|
2002
|
1.14
|
|
2
|
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
|
J Neurochem
|
2007
|
1.12
|
|
3
|
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
|
Neurobiol Dis
|
2011
|
1.01
|
|
4
|
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.
|
Brain
|
2012
|
0.96
|
|
5
|
Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons.
|
J Neurosci
|
2002
|
0.93
|
|
6
|
Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism.
|
Neurobiol Dis
|
2008
|
0.90
|
|
7
|
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
|
J Neurochem
|
2011
|
0.89
|
|
8
|
Solid lipid nanoparticles as delivery systems for bromocriptine.
|
Pharm Res
|
2008
|
0.88
|
|
9
|
Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.
|
J Neurochem
|
2008
|
0.88
|
|
10
|
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex.
|
Eur J Neurosci
|
2004
|
0.86
|
|
11
|
NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathways.
|
J Neurochem
|
2007
|
0.85
|
|
12
|
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.
|
Exp Neurol
|
2011
|
0.85
|
|
13
|
Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease.
|
Mol Cell Neurosci
|
2004
|
0.84
|
|
14
|
Loss of cortical GABA terminals in Unverricht-Lundborg disease.
|
Neurobiol Dis
|
2012
|
0.82
|
|
15
|
Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
|
Exp Neurol
|
2010
|
0.80
|
|
16
|
Nociceptin/orphanin FQ receptor knockout rats: in vitro and in vivo studies.
|
Neuropharmacology
|
2010
|
0.80
|
|
17
|
Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine.
|
Mol Cell Neurosci
|
2005
|
0.79
|
|
18
|
Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice.
|
J Neurochem
|
2010
|
0.78
|
|
19
|
Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4).
|
Peptides
|
2010
|
0.78
|
|
20
|
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro.
|
Br J Pharmacol
|
2002
|
0.77
|
|
21
|
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands.
|
Neuropharmacology
|
2013
|
0.76
|